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The Northern California Sickle Cell Center at Children’s 
Hospital Oakland offers comprehensive pediatric and adult 
services to 700 active patients with sickle cell disease (SCD). 
This includes 6900 outpatient visits and approximately 5000 
inpatient days with an average length of stay of 4.7 days. 
Additionally, this includes a reference hemoglobin biology 
laboratory, a stem cell transplantation program, a 20-bed 
pheresis transfusion unit, an ambulatory center, and a 
centralized inpatient floor. Specialized services for nutrition, 
physiatry, pulmonary disease, brain function, transition 
program for adolescents, mental health services, and 
transfusion are included in our core program. The program 
focuses on prevention and treatment of complications. 
Prevention and treatment of brain injury is a major focus 
of the program. Approximately 6 percent of our annual 
transcranial Doppler ultrasonographs (TCDs) are abnormal, 
requiring transfusion therapy, and 16 percent of conditional 
TCDs eventually have converted to abnormal in our program, 
resulting in transfusion therapy.1 Preliminary studies suggest 
children with asymptomatic neuroimaging abnormalities have 
neurocognitive injury and both progress with time. Transfusion 
therapy is being studied to prevent this progression presently. 
Although more than 100 patients are receiving hydroxyurea 
therapy in our program, transfusion therapy remains a core 
treatment for many patients.
Chronic transfusion therapy is recommended for the 
prevention and for the treatment of many complications 
of SCD.1 Patients are transfused in a 17-bed ambulatory 
transfusion unit with weekend availability. All transfused 
patients are followed in a comprehensive transfusion program 
that offers red blood cell (RBC) pheresis, quantitative 
monitoring of body iron stores, and access to multiple iron 
chelators. Sixty pediatric patients and 40 adults are receiving 
chronic transfusions, with 40 patients receiving chronic RBC 
pheresis.
Transfusion Protocol
All patients upon enrollment in our program and 
before transfusion therapy undergo detailed pretransfusion 
testing for RBC antigens by serology and genotyping. Such 
genotyping has resulted in improved matching of individuals. 
Since 1994, all patients received blood matched for C, c, E, e, 
and K in addition to ABO and D. Once an antibody was made, 
phenotypic matching was extended to include Fya, Fyb, Jka, Jkb, 
S, s, M, and N. All patients commencing chronic transfusion 
have antibody formation and reactions monitored and 
recorded on a monthly basis. Each transfusion is preceded by 
a complete blood count, antibody screening, and hemoglobin 
S level. Patients initially undergo a routine antibody screening 
with a three-cell panel using a gel method (Ortho ID-MTS, 
Ortho Clinical Diagnostics, Rochester, NY). Positive screens 
trigger antibody identification with a ten-cell panel. When 
possible, absorption methods to detect autoantibodies are 
performed. Any antibodies with complex specificities are sent 
to the Blood Bank of the Pacific.
To maintain an extended phenotyping RBC transfusion 
program for patients with SCD, a minority donor recruitment 
program is supported. This program focuses on recruiting 
minority donors at alternative sites, such as churches, 
hospitals, and community events. Ethnic matching of units 
is not performed; however, all units are screened for sickle 
cell trait by solubility testing. Units are stored in CPDA-1 or 
Adsol S-1 (Baxter Corp., Round Lake, IL). There is no age 
requirement for the donor blood unit beyond standard life 
guidelines except in selected cases. Clinical data are developing 
that support the use of fresh blood. We are attempting to 
provide units less than 2 weeks old, but this is very difficult 
and has not been a requirement for most patients. All units 
undergo leukocyte reduction at the blood bank. Therefore, 
cytomegalovirus (CMV) screening, as well as irradiation 
of units, is not used except in the immediate pretransplant 
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management of patients. Although many programs irradiate 
RBCs, there is no evidence of benefit to patients with SCD, and 
there is a suggestion of shortened RBC survival.
Methods of Transfusion
Simple transfusions in the ambulatory setting, designed 
to maintain a pretransfusion hemoglobin (Hb) greater than 
9 g/dL, is our standard protocol.2 When hemoglobin S (HbS) 
levels are high, the maximum Hb is maintained at less than 
11 g/dL because of the risk of hyperviscosity. In chronically 
transfused patients with low HbS levels, maximum Hb levels 
as high as 12 g/dL are maintained. RBC pheresis is routinely 
used for initial stroke management and in the care of patients 
with high baseline Hb or difficulty in maintaining iron balance 
with iron chelation therapy.3,4
Children’s Hospital Oakland Experience
Since 1990, we have prospectively been following the 
efficacy and complications of a chronic RBC transfusion. In 
1992, we initiated a mandatory leukoreduced RBC program, 
and in 1994, we initiated a mandatory extended RBC matching 
for ABO, D, Cc, Ee, and K. In this program, once an antibody 
was formed, patients received units fully matched for Fya, Fyb, 
Jka, Jkb, S, s, M, and N. On rare occasions, patients who were 
unable to receive phenotypically matched units because of 
emergencies were transfused with D– K–  RBC units. None 
of these patients developed antibodies. Before the initiation of 
phenotypically matched units, a retrospective review of our 
data indicated an alloimmunization rate of approximately 2 
percent to 3 percent per unit of exposure. After initiation of our 
matching program, the overall alloimmunization rate fell to 
0.05 antibodies per 100 units transfused.5 The alloantibodies 
that developed were anti-Lea, -M, -D, -C, -Kpa, and -rhi. The 
workup suggested one patient was a partial D who typed as 
D+. At least three of these patients were transfused at outside 
institutions transiently. No patients developed progressive 
alloimmunization. Three autoantibodies occurred. These were 
warm IgG antibodies. All three autoantibodies were transient 
and did not prevent transfusion. We used the least incompatible 
units with complete phenotyping, and there was no evidence 
of hemolysis. In contrast, we did experience, in thalassemia, 
two patients with autoimmune hemolytic anemia that was 
associated with prior alloimmunization. Both patients were 
alloimmunized before enrolling in our program. One patient 
responded completely to Rituximab. The other patient showed 
transient elimination of the antibody when rechallenged with 
phenotype-matched units. This patient successfully underwent 
a stem cell transplantation using Alemtuzumabe (Campath, 
Genzyme, Inc., Cambridge, MA) which resulted in complete 
elimination of the autoantibody. Before our matching program, 
hemolytic transfusion reactions occurred in 11 percent of our 
chronically transfused population. After the initiation of our 
extended RBC matching program, we have experienced only 
one hemolytic reaction. This patient was noted to have a lack 
of response to transfusion with a rising HbS level. The workup 
identified anti-Lea and -M, two antibodies that are generally 
not associated with hemolysis. The patient has been transfused 
for several years after this event and has not developed any 
transfusion complications.
Management of Complications
Prevention of Transfusion Reactions
Alloimmunization is one of the most important 
complications of transfusion therapy and SCD.6,7 The risk of 
alloimmunization to RBC antigens varies among individuals. 
There clearly are genetic determinants of patients with in-
creased rate of antibody formation. Clinical and experimental 
data indicate that HLA molecules, proinflammatory cytokines 
(e.g., interleukin [IL] 1, IL-6, IL-8), costimulatory molecules 
(e.g., IL-10, transforming growth factor), and signaling 
molecules (e.g., cytotoxic T-lymphocyte antigen 4) associated 
with CD4-regulatory T cells mediate the response to 
alloimmunization.8,9 In addition, factors such as splenectomy, 
patient age, and disease subtype appear to be important. The 
two most important factors responsible for alloimmunization 
in patients with SCD are the number of transfusion exposures 
and the disparity in RBC phenotype between donor and 
recipient.10–12 With standard RBC matching, eventually 40 
percent to 80 percent of recurrently transfused adult sickle cell 
anemia patients are alloimmunized.10 Our first approach to 
this problem is using limited and extended RBC phenotyping.
Many of the antibodies are not persistent, and patients are 
receiving transfusions at multiple locations without information 
about their prior transfusion records.10 Unfortunately there 
is no central blood bank registry for patient reactions. The 
transfusion of RBCs to a patient previously sensitized to 
a transient clinically significant antigen is one of the most 
common causes of transfusion reactions. To address this, each 
patient is given a card or letter with his or her RBC phenotype 
and transfusion history. The patient is educated to present this 
information at each facility.
To prevent alloimmunization, all patients with SCD 
undergo complete antigen RBC typing. The RBC phenotype 
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is augmented by a genotype in patients who are chronically 
transfused.13 The genotype results enable the identification 
of patients with hybrid alleles at risk for undetected antibody 
reactions.14,15 For example, altered C antigens are present in as 
many as 20 percent of African Americans. These patients type 
serologically as C+ but make anti-C.16 Patients without a history 
of immunologic reactions receive prospectively matched units 
for C, E, and K, as well as high-risk mutations uncovered 
with genotype testing.14 Once a clinically significant antibody 
develops, patients undergo extended matching. Duffy, Kidd, 
Lewis, and MNS are included. The reference blood bank is 
incorporated in a prospective transfusion regimen to plan for 
blood transfusion requests.
Autoantibodies
A positive direct antiglobulin test (DAT) is a common 
complication in transfused patients with SCD that results 
in significant clinical, laboratory, and financial problems.4,17 
Inflammation, existing alloantibody, and genetic polymorph-
isms are risk factors. A positive DAT needs to be evaluated 
in the clinical setting. This includes laboratory evaluation 
for evidence of increased hemolysis and a detailed review of 
the transfusion history to rule out a primary immunization. 
A review of the patient’s drug history should be performed. 
Drugs such as cephalosporins are associated with positive 
DATs but rarely with hemolysis. Detailed evaluation of the 
positive DAT for IgG complement, strength, and temperature 
are necessary. Elution of the antibody and evaluation for a 
masked alloantibody are necessary. In general, the strength 
of the DAT does reflect the risk of hemolysis. Nonspecific, 
weakly positive DATs are commonly stimulated by chronic 
transfusions and are usually transient. Many patients have 
a polyspecific positive DAT that is negative on follow-up 
evaluation with monospecific reagents. Occasionally, they 
do have specificity. Our approach is to aggressively evaluate 
the patients with a positive DAT, including elution and 
specificity. If the patient shows no evidence of hemolysis or 
the DAT is weak, we continue the transfusion program using 
phenotypically matched units.
Hemolytic Transfusion Reaction With Negative 
Evaluation
Patients with SCD are prone to DAT-negative 
hyperhemolytic crisis.18,19 This occurs usually in chronically 
transfused patients who have clinical findings during an 
acute illness consistent with a hemolytic transfusion reaction. 
The cause of this serious event is unknown. Older, stored 
donor RBCs may accelerate hemolysis in patients with 
SCD by eryptosis with phosphatidylserine activation of an 
inflammatory hemolytic process. Clinicians have documented 
a bystander effect in which hemolysis of the transfused units 
induces hemolysis of the patient’s RBCs. Treating severe 
hemolytic transfusion reactions, whether DAT positive or 
negative, is difficult. Our approach is to avoid transfusions and 
use conservative therapy if possible. Lifesaving transfusions 
should not be withheld. Support of these patients is possible. 
We have used intravenous immunoglobulin (IVIG) therapy, 
high-dose erythropoietin, and steroids. Our success has been 
limited. Recently, we have found Rituximab to be effective in 
modulating the hemolysis.20
In summary, transfusion therapy is increasingly used 
despite advances in treatment of SCD. As patients age, 
transfusion exposure significantly increases. Transfusion 
complications can be largely prevented by implementation of 
preventive strategies.21,22 These are not routinely implemented, 
largely because of concerns for cost. Detailed studies 
comprehensively evaluating the risk and benefit, focusing on 
cost, have not been completed.23 Several programs describe cost 
savings based on decreased need to search for specialty units 
because of fewer antibodies. Others have indicated the cost 
decreases because of the expansion of minority recruitment and 
the increased availability of rare antigen donors.24 However, 
patient safety should supersede cost savings. Therefore, our 
approach has been to focus on decreasing clinical morbidity. 
We have previously demonstrated that phenotypically matched 
units dramatically decrease the rate of alloimmunization. We 
are presently working to expand our donor pool, evaluate the 
benefit of genotyping, and identify clinically useful genetic risk 
factors for transfusion reactions.
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